Positive News SentimentPositive NewsNASDAQ:OMGA Omega Therapeutics (OMGA) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free OMGA Stock Alerts $3.65 +0.10 (+2.82%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.59▼$3.7750-Day Range$3.32▼$4.3352-Week Range$1.30▼$10.09Volume274,990 shsAverage Volume2.22 million shsMarket Capitalization$201.26 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Omega Therapeutics alerts: Email Address Omega Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside228.8% Upside$12.00 Price TargetShort InterestBearish19.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.89Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.93) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.07 out of 5 starsMedical Sector632nd out of 938 stocksBiological Products, Except Diagnostic Industry108th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingOmega Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Omega Therapeutics has a forecasted upside of 228.8% from its current price of $3.65.Amount of Analyst CoverageOmega Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted19.00% of the float of Omega Therapeutics has been sold short.Short Interest Ratio / Days to CoverOmega Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omega Therapeutics has recently increased by 4.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOmega Therapeutics does not currently pay a dividend.Dividend GrowthOmega Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OMGA. Previous Next 3.8 News and Social Media Coverage News SentimentOmega Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Omega Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for OMGA on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows9 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omega Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders57.00% of the stock of Omega Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.47% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Omega Therapeutics are expected to grow in the coming year, from ($1.93) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omega Therapeutics is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Omega Therapeutics is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmega Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Omega Therapeutics Stock (NASDAQ:OMGA)Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More OMGA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMGA Stock News HeadlinesMarch 28, 2024 | globenewswire.comOmega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic UpdateMarch 16, 2024 | finance.yahoo.comOMGA Apr 2024 12.500 callMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 12, 2024 | markets.businessinsider.comIntrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem PandyaMarch 6, 2024 | globenewswire.comOmega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024January 26, 2024 | benzinga.comHow Is The Market Feeling About Omega Therapeutics?January 16, 2024 | seekingalpha.comOmega Therapeutics: The Next Weight Loss Drug RunnerJanuary 6, 2024 | morningstar.comOmega Therapeutics Inc OMGAMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.January 5, 2024 | finance.yahoo.comNovo Nordisk (NVO) Up on $1.1B Research Deals With 2 BiotechsJanuary 5, 2024 | finance.yahoo.comOmega (OMGA) Up 95% on Obesity Drug Deal With Novo NordiskJanuary 4, 2024 | msn.comOmega (NASDAQ:OMGA) Skyrockets After Research Deal With Novo NordiskJanuary 4, 2024 | realmoney.thestreet.comOmega collaboration with Novo Nordisk 'validation' of OEG platform, says WedbushJanuary 4, 2024 | fool.comWhy Novo Nordisk Stock Crushed the Market TodayJanuary 4, 2024 | ca.finance.yahoo.comOMGA Feb 2024 2.500 callJanuary 4, 2024 | markets.businessinsider.comFamed Obesity Drug Maker Novo Nordisk Inks Collaborations For Cardiometabolic DiseasesJanuary 4, 2024 | finance.yahoo.comNovo Nordisk enters research partnerships with biotech firmsJanuary 4, 2024 | finance.yahoo.comNovo Nordisk, The Weight-Loss Kingpin, Breaks Out After Inking Two New Deals In ObesityJanuary 4, 2024 | investorplace.comWhy Is Omega Therapeutics (OMGA) Stock Up 111% Today?January 4, 2024 | marketwatch.comOmega Therapeutics Stock Surges 99% Following Pact with Novo Nordisk to Treat obesityJanuary 4, 2024 | msn.comNovo Nordisk signs research deals on cardiometabolic diseasesJanuary 4, 2024 | markets.businessinsider.comNovo Nordisk Enters Collaboration Agreements With Omega And CellarityJanuary 2, 2024 | finance.yahoo.comOmega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 4, 2023 | finance.yahoo.comOmega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNovember 24, 2023 | benzinga.comOmega Therapeutics Stock (NASDAQ:OMGA) Earnings Dates and Earning CallsNovember 24, 2023 | benzinga.comOmega Therapeutics Stock (NASDAQ:OMGA) Insider TradesNovember 20, 2023 | finance.yahoo.comOmega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare ConferenceSee More Headlines Receive OMGA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OMGA CUSIPN/A CIK1850838 Webwww.omegatherapeutics.com Phone617-949-4360FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+228.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,700,000.00 Net Margins-3,802.89% Pretax Margin-3,802.89% Return on Equity-107.79% Return on Assets-57.69% Debt Debt-to-Equity Ratio0.21 Current Ratio3.80 Quick Ratio3.80 Sales & Book Value Annual Sales$2.07 million Price / Sales97.23 Cash FlowN/A Price / Cash FlowN/A Book Value$2.21 per share Price / Book1.65Miscellaneous Outstanding Shares55,140,000Free Float23,711,000Market Cap$201.26 million OptionableOptionable Beta1.88 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Mahesh Karande (Age 50)President, CEO & Board Director Comp: $812.88kMs. Ling Zeng Esq. (Age 55)J.D., Chief Legal & Administrative Officer and Secretary Comp: $519.36kDr. Yan Moore M.D. (Age 57)Chief Medical Officer Comp: $1.14MMr. Joshua Reed M.B.A. (Age 50)Chief Financial Officer Dr. Sivakesava Sakhamuri Ph.D.Senior VP and Head of Technical Operations & QualityDr. Thomas McCauley (Age 55)Chief Scientific Officer Comp: $588.5kMr. Anthony MullinChief People OfficerMr. Charles O'Donnell Ph.D.VP and Head of Computational Genomics & Data SciencesMore ExecutivesKey CompetitorsGraphite BioNASDAQ:GRPHInventivaNASDAQ:IVAInnate PharmaNASDAQ:IPHAGenfitNASDAQ:GNFT10X Capital Venture Acquisition Corp. IIINYSE:VCXBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 23,553 shares on 3/11/2024Ownership: 2.737%Goldman Sachs Group Inc.Sold 6,900 shares on 3/1/2024Ownership: 0.024%Vanguard Group Inc.Bought 23,553 shares on 2/15/2024Ownership: 2.737%Barclays PLCBought 29,013 shares on 2/15/2024Ownership: 0.085%Citadel Advisors LLCSold 1,500 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions OMGA Stock Analysis - Frequently Asked Questions Should I buy or sell Omega Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMGA shares. View OMGA analyst ratings or view top-rated stocks. What is Omega Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 1-year price targets for Omega Therapeutics' stock. Their OMGA share price targets range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 228.8% from the stock's current price. View analysts price targets for OMGA or view top-rated stocks among Wall Street analysts. How have OMGA shares performed in 2024? Omega Therapeutics' stock was trading at $3.01 at the start of the year. Since then, OMGA shares have increased by 21.3% and is now trading at $3.65. View the best growth stocks for 2024 here. When is Omega Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our OMGA earnings forecast. How were Omega Therapeutics' earnings last quarter? Omega Therapeutics, Inc. (NASDAQ:OMGA) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.09. Omega Therapeutics had a negative net margin of 3,802.89% and a negative trailing twelve-month return on equity of 107.79%. When did Omega Therapeutics IPO? Omega Therapeutics (OMGA) raised $126 million in an IPO on Friday, July 30th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Who are Omega Therapeutics' major shareholders? Omega Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.74%), Vanguard Group Inc. (2.74%), Blue Owl Capital Holdings LP (1.91%), Northern Trust Corp (0.36%), Barclays PLC (0.09%) and Murphy Pohlad Asset Management LLC (0.03%). Insiders that own company stock include Flagship Pioneering Inc and Richard A Young. View institutional ownership trends. How do I buy shares of Omega Therapeutics? Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OMGA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omega Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.